Kevin Robert Lind - 30 Jul 2026 Form 4 Insider Report for Apnimed, Inc. (APMD)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: APMD
Reported as of: 30 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Aug 2026, 16:01:09 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/Kevin R. Lind, Attorney-in-Fact

Key filing fact

Kevin Robert Lind filed Form 4 for Apnimed, Inc. (APMD) on 03 Aug 2026.

Key facts

This page summarizes Kevin Robert Lind's Form 4 filing for Apnimed, Inc. (APMD).
7 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 03 Aug 2026, 16:01.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001677036 Primary reporting owner

Lind Kevin Robert

Relationship: Chief Executive Officer, Director
Address: APNIMED, INC., 39 JOHN F. KENNEDY STREET, 4TH FLOOR, CAMBRIDGE
Signature: /s/Kevin R. Lind, Attorney-in-Fact
Signature date: 03 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APMD transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -74,128
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 74,128
Exercise price: $9.50
Footnotes: F1, F2

APMD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +74,128
Change %
Price: $0.000000^*
Shares after: 74,128
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 74,128
Exercise price: $9.50
Footnotes: F1, F2

APMD transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -1,186,278
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 1,186,278
Exercise price: $8.15
Footnotes: F1, F3

APMD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +1,186,278
Change %
Price: $0.000000^*
Shares after: 1,186,278
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,186,278
Exercise price: $8.15
Footnotes: F1, F3

APMD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +108,916
Change %
Price: $0.000000^*
Shares after: 108,916
Date: 30 Jul 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 108,916
Exercise price: $16.00
Footnotes: F3

APMD transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -108,916
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 108,916
Exercise price: $16.00
Footnotes: F1, F3

APMD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +108,916
Change %
Price: $0.000000^*
Shares after: 108,916
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 108,916
Exercise price: $16.00
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.

Footnote F2

25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Footnote F3

25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.